News & Insights

In a new editorial for the Journal of Clinical Pathways, Jason Shafrin addresses the appeal of precision benefit design, identifying three key challenges to patient-centered implementation. (more…)

PHE in Health Affairs, Value in Health,and more…

Health Affairs Blog Article on Patient-Centered Formularies

PHE Senior Director Jason Shafrin and Director Mark Linthicum published an article on the importance of accounting for patient heterogeneity in formulary design and the potential use of tools to help payers understand and assess patient-centered value.

Patient-Centered Formularies: Steps In The Right Direction, But Challenges Remain. Health Affairs Blog, April 11, 2018.DOI: 10.1377/hblog20180404.510552

—

Health Affairs Blog Article on Components of Value Frameworks

PHE Scientific Advisor Anupam Jena, along with Lauren Neves and Randy Burkholder, published an article in the Health Affairs Blog on April 16, 2018, on the importance of capturing comprehensive components of the value of medical innovations in value frameworks.

Do Value Frameworks Fully Capture The Value Of Innovation? Health Affairs Blog, April 16, 2018.DOI: 10.1377/hblog20180409.228386

—

Value in Health Study on the Impact of Improved Mobility

PHE researchers quantified the impact of improved mobility on using PHE’s proprietary microsimulation THEMIS, finding that improvements in mobility are likely to lead to significant reductions in medical expenditures and nursing home utilization and significant increases in employment.

Kabiri M, et al. The Long-Term Health and Economic Value of Improved Mobility among Older Adults in the United States. Value in Health. 2018. In Press.

—

Pharmaceutical Executive Article on the Role of Pharmaceutical Companies in Value Assessment

PHE’s Ross Maclean and Jeroen Jansen published an article in Pharmaceutical Executiveon the role of pharmaceutical companies in conducting transparent and relevant evaluations of value, advocating an open-source approach to conducting cost-effectiveness evaluations.

Transparent and Relevant Evaluations of Value: An Active Role for Pharma

Precision’s All Access is our bimonthly newsletter with original content written by our payer experts for market access leaders. (more…)

In part 2 of their Guest Commentary series, Precision’s Todd Edgar, Alex Grosvenor, and Kellie Rademacher highlight the takeaways of the NOR-SWITCH trial and how the EU’s view of biosimilars as therapeutic alternatives is influencing US policy. (more…)

Precision’s Ross Maclean and Jeroen Jansen encourage biopharma and medical device industries to embrace the developments around value assessment and to take a leading role in improving the transparency of cost-effectiveness evaluations.  (more…)

In a feature in Pharma Live, Precision’s Jeremy Schafer and Maureen Hennessy predict that the projected growth in healthcare spend is creating an inevitable marketplace shift from volume to value. (more…)

With increased biomarker and specialty lab data being incorporated into FDA submissions, drug developers are running into challenges as they prepare data that comply with new regulatory requirements. (more…)

In Part 1 of a two-part series, Todd Edgar, Alex Grosvenor, and Kellie Rademacher discuss EU biosimilar policies and their impact on the US approach, with a focus on payer coverage. (more…)

In an original article appearing in Journal of Clinical Pathways, Ashwin Athri, SVP Precision Promotional Effectiveness, discusses how variations in health systems influence oncology practices. (more…)